Amgen Inc.

Aarif Yusuf Khakoo

Zhihua Ma

Gayathri Swaminath

Yinhong Chen

Jonathan B Houze

Paul John Dransfield

Vatee Pattaropong

Wen-Chen Yeh

Su-Jen Lai

Julie Anne Heath

Nobuko Nishimura

David John Kopecky

Ning Chen

Xiaoqi Chen

Zice Fu

Alan C Cheng

Xiaodong Wang

Mikkel V Debenedetto

Jeffrey Thomas Mihalic

Richard V Connors

Steven H Olson

James S Harvey

Julio Cesar Medina

Frank Kayser

Xiaohui Du

Matthew R Kaller

Daniel B Horne

Jeffrey Deignan

Kevin Chao Yang

Ted Charles Judd

Simon J Hedley

Lawrence R McGee

Robert P Farrell

Charles Kreiman

Lars V Heumann

Malgorzata Wanska

Ankit Sharma

Philip Dean Ramsden

Matthew Irvine Brown

David C Moebius

Sujen Lai

Matthew Brown

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Growing community of inventors

Woodside, CA, United States of America

Aarif Yusuf Khakoo